Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Mutations across diverse domains of ShXDR1 lead to multi-drug resistance in Clarireedia jacksonii.

PROVIDER: PRJNA1112905 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR29070500_1.fastq.gz	Fastqsanger.gz
	SRR29070500_2.fastq.gz	Fastqsanger.gz
	SRR29070501_1.fastq.gz	Fastqsanger.gz
	SRR29070501_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 55

Similar Datasets

Project description:Genome-wide transcriptional analyses of Clarireedia jacksonii isolates associated with multi-drug resistance

| PRJNA1007393 | ENA

Clarireedia jacksonii

Project description:Clarireedia jacksonii overview

| PRJNA1259668 | ENA

Project description:Clarireedia jacksonii genome sequencing, assembly, and annotation

| PRJNA1216260 | ENA

Clarireedia jacksonii strain:SH44

Project description:Clarireedia jacksonii strain:SH44 Genome sequencing and assembly

| PRJNA288039 | ENA

Clarireedia jacksonii strain:LWC10

Project description:Clarireedia jacksonii strain:LWC10 Genome sequencing and assembly

| PRJNA288036 | ENA

Clarireedia jacksonii strain:MB01 | isolate:MB01

Project description:Clarireedia jacksonii strain:MB01 | isolate:MB01 Genome sequencing and assembly

| PRJNA288040 | ENA

Clarireedia jacksonii

Project description:Transcriptome analysis of Clarireedia jacksonii LT586 treated with Bacillus cereus B694

| PRJNA1259167 | ENA

Multiazole resistance in clinical and environmental fungal isolates

Project description:Whole genome sequencing of SYBARIS Aspergillus spp. known to be multi-drug resistant and difficult to treat. Aim of this experiment is to investigate the genetic basis of susceptibility to disease and elucidate molecular mechanisms of drug resistance in these strains.

2016-04-30 | E-SYBR-1 | biostudies-arrayexpress

High resolution landscape of an antibiotic binding site

Project description:Antibiotic binding sites are located in important domains of essential enzymes and have been extensively studied in the context of resistance mutations, however their study is limited by positive selection. Using multiplex genome engineering1 to overcome this constraint, we generate and characterize a collection of 760 single residue mutants encompassing the entire rifampicin binding site of E. coli RNA polymerase (RNAP). By genetically mapping drug-enzyme interactions, we identify an alpha helix where mutations dramatically enhance or disrupt rifampicin binding. We find mutations in this region that prolong antibiotic binding, converting rifampicin from a bacteriostatic to bactericidal drug by inducing lethal DNA breaks. The latter are replication-dependent, indicating that rifampicin kills by causing detrimental transcription-replication conflicts at promoters. We also identify additional binding site mutations that greatly increase the speed of RNAP. Fast RNAP depletes the cell of nucleotides, alters cell sensitivity to different antibiotics, and provides a cold growth advantage. Finally, by mapping natural rpoB sequence diversity, we discover functional rifampicin binding site mutations that alter RNAP properties or confer drug resistance occur frequently in nature.

2023-08-01 | GSE236920 | GEO

Drug specific epigenetic reprogramming leads to increased cellular invasion in ERα positive breast cancer via de novo cholesterol biosynthesis.

Project description:Endocrine therapy resistance remains a critical problem in the treatment of estrogen receptor alpha (ERα) breast cancer. Endocrine therapies target ERα via different modes of action. Drug resistance involves drug specific remodeling of the transcriptional and regulatory landscape. Using epigenomics and transcriptomics, we demonstrate that resistance to aromatase inhibitors (AI) induces phenotypical changes through epigenetic activation of cholesterol biosynthesis (CB) and keratin 80. Epigenetic activation is stable and involves both large topological domains and punctuated activation of single enhancers and super-enhancers. Specialized cancer cells expressing high levels of keratin 80 lead invasion through the extracellular matrix. Strikingly, we demonstrate that anti-cholesterol strategies can effectively arrest breast cancer invasion. Our work identifies a robust strategy to target resistant invasive breast cancer.

2015-12-31 | GSE60517 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data